Drug monitoring of sirolimus and everolimus

LaboratoriumsMedizin

Volumn 27, Issue 5-6, 2003, Pages 222-227

  Armstrong, Victor W ^a   Streit, Frank ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Everolimus; Sirolimus; Tandem mass spectrometry; Therapeutic drug monitoring

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; EVEROLIMUS; GLYCOPROTEIN P; MACROLIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MULTICENTER STUDY; NEPHROTOXICITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0038817791     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/LabMed.2003.034     Document Type: Review

References (33)

1. MacDonald A. Improving tolerability of immunosuppressive regimens. Transplantation 2001;72:S105-S112.
2. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000;22(Suppl B):B101-B121.
3. Kovarik JM, Kaplan B, Tedesco SH, Kahan BD, Dantal J, Vitko S, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002;73:920-925.
4. Streit F, Christians U, Schiebel HM, Napoli KL, Ernst L, Linck A, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem 1996;42:1417-1425.
5. Streit F, Christians U, Schiebel HM, Meyer A, Sewing KF. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. Drug Metab Dispos 1996;24:1272-1278.
6. Christians U, Sattler M, Schiebel HM, Kruse C, Radeke HH, Linck A, Sewing KF. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos 1992;20:186-191.
7. Yatscoff RW, Wang P, Chan K, Hicks D, Zimmerman J. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 1995;17:666-671.
8. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998;63:48-53.
9. Zimmerman JJ, Ferron GM, Lim HK, Parker V. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol 1999;39:1155-1161.
10. Kahan BD, Wong RL, Carter C, Katz SH, Von Fellenberg J, Van Buren CT, Appel-Dingemanse S. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1999;68:1100-1106.
11. Kovarik JM, Hartmann S, Figueiredo J, Rordorf C, Golor G, Lison A, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002;22:154-159.
12. Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002;42:95-99.
13. Yatscoff R, LeGatt D, Keenan R, Chackowsky P. Blood distribution of rapamycin. Transplantation 1993;56:1202-1206.
14. Kahan BD, Murgia MG, Slaton J, Napoli K. Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Ther Drug Monit 1995;17:672-675.
15. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997;37:405-415.
16. Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer SC, et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 2001;70:425-430.
17. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71:271-280.
18. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194-202.
19. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 2002;24:53-58.
20. Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit 2001;23:559-586.
21. Kahan BD, Napoli KL, Kelly PA, Podbielski J, Hussein I, Urbauer DL, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000;14:97-109.
22. Yatscoff RW, Boeckx R, Holt DW, Kahan BD, LeGatt DF, Sehgal S, et al. Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Ther Drug Monit 1995;17:676-680.
23. Salm P, Taylor PJ, Pillans PI. Analytical performance of microparticle enzyme immunoassay and HPLC-tandem mass spectrometry in the determination of sirolimus in whole blood. Clin Chem 1999;45:2278-2280.
24. Willis C, Taylor PJ, Salm P, Tett SE, Pillans PI. Quantification of free mycophenolic acid by high-performance liquid chromatography-atmospheric pressure chemical ionisation tandem mass spectrometry [In Process Citation]. J Chromatogr B Biomed Sci Appl 2000;748:151-156.
25. Taylor PJ, Johnson AG. Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 1998;718:251-257.
26. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem 2002;48:955-958.
27. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal Chem 1998;70:882-889.
28. King R, Bonfiglio R, Fernandez-Metzler C, Miller-Stein C, Olah T. Mechanistic investigation of ionization suppression in electrospray ionization. J Am Soc Mass Spectrom 2000;11:942-950.
29. Holt DW, Lee T, Jones K, Johnston A. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin Chem 2000;46:1179-1183.
30. Salm P, Tresillian MJ, Taylor PJ, Pillans PI. Stability of sirolimus (rapamycin) in whole blood. Ther Drug Monit 2000;22:423-426.
31. Salm P, Taylor PJ, Lynch SV, Pillans PI. Quantification and stability of everolimus (SDZ RAD) in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 772:283-290.
32. Deters M, Kirchner G, Resch K, Kaever V. Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS). Clin Chem Lab Med 2002;40:285-292.
33. Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 2002;42:222-228.